Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,118.00
Bid: 12,120.00
Ask: 12,124.00
Change: 68.00 (0.56%)
Spread: 4.00 (0.033%)
Open: 11,966.00
High: 12,162.00
Low: 11,966.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Sterling edges up vs euro on Brexit optimism; short positions reduced

Mon, 26th Oct 2020 12:28

* Graphic: World FX rates in 2020 http://tmsnrt.rs/2egbfVh

* Graphic: Trade-weighted sterling since Brexit vote http://tmsnrt.rs/2hwV9Hv
(Updates prices, adds comment)

By Elizabeth Howcroft

LONDON, Oct 26 (Reuters) - Cautious currency markets kept
the pound subdued against a stronger dollar on Monday, but
sterling strengthened against the euro as the current phase of
Brexit negotiations was extended until Wednesday.

The dollar strengthened, equities fell, and markets were
broadly risk-off. Analysts cited new lockdowns in Europe and
record-high daily virus cases in the United States, as well as a
lack of progress towards U.S. fiscal stimulus.

But the pound took some support from signs of progress in
Brexit trade talks. The EU's chief negotiator, Michel Barnier,
will be in London until Wednesday to try and clinch a deal,
after which negotiations will switch to Brussels.

"Right now there’s a bit of optimism creeping in from the
weekend developments - the extension of the talks until
Wednesday," said Ned Rumpeltin, head of European currency
strategy at TD Securities.

"The fact that France might be signalling some movement on
fish is encouraging. We’ll see how that plays out," he said.

At 1051 GMT, the pound was little changed against the
dollar, at $1.3051. It was up around 0.4% against the
euro, at 90.58 pence.

Britain and the EU have just over two months left to agree
on their future trading relationship, before a Dec. 31 deadline.

There are some hopes that a Brexit deal can be reached, with
Ireland's Deputy Prime Minister and Northern Ireland minister
Brandon Lewis expressing optimism on Sunday.

Asked about reports that the UK was waiting to see the
result of the U.S. elections before making a decision about
Brexit, Prime Minister Boris Johnson said the two were "entirely
separate".

Goldman Sachs FX strategists said that Brexit developments
were looking positive.

"Despite sterling's underperformance on Friday, we continue
to see a path for a sharply higher GBP/USD cross into year-end,"
they wrote in a note.

Speculators reduced their net short position on the pound in
the week to Oct. 20, for the third week running, weekly CFTC
futures data showed.

TD Securities' Rumpeltin said that this could be due to a
combination of market participants reining in positioning before
the U.S. election and that the range of possibilities around
Brexit are narrowing.

Elsewhere, news that a vaccine being developed by British
drugmaker AstraZeneca and the University of Oxford
produced an immune response in elderly and young people failed
to bolster market sentiment.

Britain's health minister said his central expectation was
for a vaccine to be rolled out for the first half of 2021.
(Reporting by Elizabeth Howcroft; editing by Emelia
Sithole-Matarise, Larry King)

More News
Today 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
Today 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.